Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Intangibles (2018 - 2025)

Historic Intangibles for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $8532.0.

  • China SXT Pharmaceuticals' Intangibles fell 4633.29% to $8532.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8532.0, marking a year-over-year decrease of 4633.29%. This contributed to the annual value of $11808.0 for FY2025, which is 3818.12% down from last year.
  • China SXT Pharmaceuticals' Intangibles amounted to $8532.0 in Q3 2025, which was down 4633.29% from $11808.0 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Intangibles ranged from a high of $85728.0 in Q1 2022 and a low of $8532.0 during Q3 2025
  • Moreover, its 5-year median value for Intangibles was $25191.0 (2023), whereas its average is $34747.4.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Intangibles surged by 807.56% in 2021, and later plummeted by 6749.25% in 2023.
  • Quarter analysis of 5 years shows China SXT Pharmaceuticals' Intangibles stood at $42353.0 in 2021, then fell by 27.46% to $30724.0 in 2022, then fell by 26.72% to $22514.0 in 2023, then decreased by 29.39% to $15898.0 in 2024, then crashed by 46.33% to $8532.0 in 2025.
  • Its Intangibles stands at $8532.0 for Q3 2025, versus $11808.0 for Q1 2025 and $15898.0 for Q3 2024.